CAR-T Therapies in the Follicular Lymphoma Treatment Landscape

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

The safety profile of sonrotoclax was generally well-tolerated, and emergent toxicities were manageable in patients with mantle cell lymphoma.

The CD19 t-haNK therapy alone and in combination with rituximab achieved complete responses and no significant toxicities in 2 patients with late-stage WM.